SYNTAX及其衍生评分被应用于复杂冠心病选择血运重建策略的研究进展

doi:10.24920/004085

摘要/Abstract

摘要：

复杂冠心病因其冠状动脉解剖结构复杂、临床因素多变、血运重建难度大、药物保守治疗效果有限等特点，近年来成为医学研究领域的热点。而随着血运重建技术的日臻完善和冠状动脉危险分层评分的引入，使得复杂冠心病的识别和最佳治疗方式的选择更加科学化。作为一种新兴的冠状动脉危险分层评分工具，SYNTAX及其衍生评分基于冠状动脉血管病变的复杂性及严重性，定量描述冠状动脉的病变特点，以辅助临床医师合理选择冠状动脉血运重建治疗的策略。本文总结了SYNTAX及其衍生评分在复杂冠心病中的应用情况，期望能加深临床医师对复杂冠心病不同血运重建策略抉择的认识，为复杂冠心病的救治提供参考。

关键词: 复杂冠心病, 血运重建策略, SYNTAX及其衍生评分

Abstract:

Complex coronary heart disease (CHD) has become a hot spot in medicine due to its complex coronary anatomy, variable clinical factors, difficult hemodynamic reconstruction, and limited effect of conservative drug treatment. Identifying complex CHD and selecting optimal treatment methods have become more scientific as revascularization technology has improved, and coronary risk stratification scores have been introduced. SYNTAX and its derivative scores are decision-making tools that quantitatively describe the characteristics of coronary lesions in patients based on their complexity and severity. The SYNTAX and its derivative scores could assist clinicians in rationalizing the selection of hemodynamic reconstruction treatment strategies, and have demon-strated outstanding value in evaluating the prognosis of patients with complex CHD undergoing revascularization treatment. The authors in this article summary the practical application of SYNTAX and its derivative scores in complex CHD in order to deepen the understanding of the relationship between the choice of different revascularization strategies and SYNTAX and its derived scores in complex CHD and provide a further reference for clinical treatment of complex CHD.

Key words: complex coronary heart disease, revascularization strategies, SYNTAX and its derivative scores

Yuxu Zhang, Rongruo Zeng, Ye Yang, Yin Shen. Application of SYNTAX and its Derivative Scores in the Selection of Revascularization Strategies for Complex Coronary Heart Disease[J].Chinese Medical Sciences Journal, 2022, 37(4): 340-348.

图/表 1

参考文献 60

[1]	Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015; 132(17):1667-78. doi: 10.1161/circulationaha.114.008720. doi: 10.1161/CIRCULATIONAHA.114.008720 pmid: 26503749
[2]	Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2019; 55(1):4-90. doi: 10.1093/ejcts/ezy289. doi: 10.1093/ejcts/ezy289
[3]	Hang YL. Guidelines for percutaneous coronary intervention in China (2016). Chin J Cardiol 2016; 44(5):382-400.
[4]	Ong AT, Serruys PW, Mohr FW, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J 2006; 151(6):1194-204. doi: 10.1016/j.ahj.2005.07.017. doi: 10.1016/j.ahj.2005.07.017 pmid: 16781219
[5]	Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360(10):961-72. doi: 10.1056/NEJMoa0804626. doi: 10.1056/NEJMoa0804626
[6]	Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381(9867):629-38. doi: 10.1016/s0140-6736(13)60141-5. doi: 10.1016/s0140-6736(13)60141-5
[7]	van Dongen IM, Elias J, García-García HM, et al. Value of the SYNTAX score in ST-elevation myocardial infarction patients with a concomitant chronic total coronary occlusion (from the EXPLORE Trial). Am J Cardiol 2019; 123 (7):1035-43. doi: 10.1016/j.amjcard.2018.12.028. doi: S0002-9149(19)30031-1 pmid: 30654929
[8]	Shlofmitz E, Généreux P, Chen S, et al. Left main coronary artery disease revascularization according to the SYNTAX score. Circ Cardiovasc Interv 2019; 12(9): e008007. doi: 10.1161/circinterventions.118.008007. doi: 10.1161/circinterventions.118.008007
[9]	Thuijs D, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 2019; 394(10206):1325-34. doi: 10.1016/s0140-6736(19)31997-x. doi: 10.1016/s0140-6736(19)31997-x
[10]	Park DW, Kim YH, Yun SC, et al. Complexity of atherosclerotic coronary artery disease and long-term outcomes in patients with unprotected left main disease treated with drug-eluting stents or coronary artery bypass grafting. J Am Coll Cardiol 2011; 57(21):2152-9. doi: 10.1016/j.jacc.2011.01.033. doi: 10.1016/j.jacc.2011.01.033
[11]	Magro M, Nauta S, Simsek C, et al. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: the MI SYNTAX score study. Am Heart J 2011; 161(4):771-81. doi: 10.1016/j.ahj.2011.01.004. doi: 10.1016/j.ahj.2011.01.004
[12]	Palmerini T, Genereux P, Caixeta A, et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2011; 57(24):2389-97. doi: 10.1016/j.jacc.2011.02.032. doi: 10.1016/j.jacc.2011.02.032 pmid: 21658558
[13]	Sabatine MS, Bergmark BA, Murphy SA, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet 2021; 398(10318):2247-57. doi: 10.1016/s0140-6736(21)02334-5. doi: 10.1016/S0140-6736(21)02334-5 pmid: 34793745
[14]	Yoon YH, Ahn JM, Kang DY, et al. Impact of SYNTAX score on 10-year outcomes after revascularization for left main coronary artery disease. JACC Cardiovasc Interv 2020; 13(3):361-71. doi: 10.1016/j.jcin.2019.10.020. doi: 10.1016/j.jcin.2019.10.020
[15]	Lee J, Ahn JM, Kim JH, et al. Prognostic effect of the SYNTAX score on 10-year outcomes after left main coronary artery revascularization in a randomized population: insights from the extended PRECOMBAT trial. J Am Heart Assoc 2021; 10(14): e020359. doi: 10.1161/jaha. 120.020359. doi: 10.1161/jaha. 120.020359
[16]	Garg S, Sarno G, Garcia-Garcia HM, et al. A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX Score. Circ Cardiovasc Interv 2010; 3(4):317-26. doi: 10.1161/circinterventions.109.914051. doi: 10.1161/CIRCINTERVENTIONS.109.914051 pmid: 20647561
[17]	Gao G, Zhang D, Song C, et al. Integrating the residual SYNTAX score to improve the predictive ability of the age, creatinine, and ejection fraction (ACEF) score for cardiac mortality in percutaneous coronary intervention patients. Catheter Cardiovasc Interv 2020; 95 Suppl 1:534-41. doi: 10.1002/ccd.28673. doi: 10.1002/ccd.28673
[18]	Janella BL, Campos CM, Caixeta A, et al. Assessment of long-term mortality in patients with complex coronary artery disease undergoing percutaneous intervention: comparison of multiple anatomical and clinical prognostic risk scores. EuroIntervention 2017; 13(10):1177-84. doi: 10.4244/eij-d-16-00659. doi: EIJ-D-16-00659 pmid: 28506936
[19]	Li XQ, Yin C, Li XL, et al. Comparison of the prognostic value of SYNTAX score and clinical SYNTAX score on outcomes of Chinese patients underwent percutaneous coronary intervention. BMC Cardiovasc Disord 2021; 21(1): 334. doi: 10.1186/s12872-021-02144-w. doi: 10.1186/s12872-021-02144-w
[20]	Onuk T, Güngör B, İpek G, et al. Comparison of long-term prognostic value of baseline SYNTAX and clinical SYNTAX scores in ST-segment elevation myocardial infarction patients with multivessel disease. Coron Artery Dis 2016; 27(4):311-8. doi: 10.1097/mca.0000000000000365. doi: 10.1097/mca.0000000000000365
[21]	Kawashima H, Hara H, Wang R, et al. Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction. Catheter Cardiovasc Interv 2021; 97(7): E919-e28. doi: 10.1002/ccd.29383. doi: 10.1002/ccd.29383
[22]	Song Y, Gao Z, Tang XF, et al. Impact of residual SYNTAX score and its derived indexes on clinical outcomes after percutaneous coronary intervention: data from a large single center. Chin Med J (Engl) 2018; 131(12):1390-6. doi: 10.4103/0366-6999.233958. doi: 10.4103/0366-6999.233958
[23]	Collet C, Onuma Y, Miyazaki Y, et al. Integration of non-invasive functional assessments with anatomical risk stratification in complex coronary artery disease: the non-invasive functional SYNTAX score. Cardiovasc Diagn Ther 2017; 7(2):151-8. doi: 10.21037/cdt.2017.03.19. doi: 10.21037/cdt.2017.03.19
[24]	Kundu A, Sardar P, O’Day K, et al. SYNTAX score and outcomes of coronary revascularization in diabetic patients. Curr Cardiol Rep 2018; 20(5): 28. doi: 10.1007/s11886-018-0971-1. doi: 10.1007/s11886-018-0971-1 pmid: 29572680
[25]	He J, Zhao H, Yu X, et al. SYNTAX score-Ⅱ predicts long-term mortality in patients who underwent left main percutaneous coronary intervention treated with second-generation drug-eluting stents. Int Heart J 2017; 58(3):344-50. doi: 10.1536/ihj.16-292. doi: 10.1536/ihj.16-292
[26]	Xu B, Généreux P, Yang Y, et al. Validation and comparison of the long-term prognostic capability of the SYNTAX score-Ⅱ among 1,528 consecutive patients who underwent left main percutaneous coronary intervention. JACC Cardiovasc Interv 2014; 7 (10):1128-37. doi: 10.1016/j.jcin.2014.05.018. doi: 10.1016/j.jcin.2014.05.018
[27]	Salvatore A, Boukhris M, Giubilato S, et al. Usefulness of SYNTAX score Ⅱ in complex percutaneous coronary interventions in the setting of acute coronary syndrome. J Saudi Heart Assoc 2016; 28(2):63-72. doi: 10.1016/j.jsha.2015.07.003. doi: 10.1016/j.jsha.2015.07.003
[28]	Campos CM, van Klaveren D, Farooq V, et al. Long-term forecasting and comparison of mortality in the evaluation of the Xience Everolimus eluting stent vs. coronary artery bypass surgery for effectiveness of left main revascularization (EXCEL) trial: prospective validation of the SYNTAX score Ⅱ. Eur Heart J 2015; 36(20):1231-41. doi: 10.1093/eurheartj/ehu518. doi: 10.1093/eurheartj/ehu518
[29]	Hara H, Shiomi H, van Klaveren D, et al. External validation of the SYNTAX score Ⅱ 2020. J Am Coll Cardiol 2021; 78 (12):1227-38. doi: 10.1016/j.jacc.2021.07.027. doi: 10.1016/j.jacc.2021.07.027
[30]	He JQ, Yu XP, Peng C, et al. Predictive ability of the SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery score Ⅱ for long-term mortality in patients with three-vessel coronary artery disease undergoing percutaneous coronary intervention treated with second-generation drug-eluting stents. Chin Med J (Engl) 2015; 128(16):2176-82. doi: 10.4103/0366-6999.162510. doi: 10.4103/0366-6999.162510
[31]	Takahashi K, Serruys PW, Fuster V, et al. Redevelopment and validation of the SYNTAX score Ⅱ to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. Lancet 2020; 396(10260):1399-412. doi: 10.1016/s0140-6736(20)32114-0. doi: 10.1016/S0140-6736(20)32114-0 pmid: 33038944
[32]	Yang H, Zhang Land Xu CH. Use of the SYNTAX score Ⅱ to predict mortality in interventional cardiology: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98(2): e14043. doi: 10.1097/md.0000000000014043. doi: 10.1097/md.0000000000014043
[33]	Yesin M, Çağdaş M, Kalçık M, et al. Comparison of syntax score and syntax score Ⅱ to predict “no reflow phenomenon” in patients with ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging 2017; 33 (12):1883-9. doi: 10.1007/s10554-017-1200-5. doi: 10.1007/s10554-017-1200-5
[34]	Campos CM, van Klaveren D, Iqbal J, et al. Predictive performance of SYNTAX score Ⅱ in patients with left main and multivessel coronary artery disease-analysis of CREDO-Kyoto registry. Circ J 2014; 78(8):1942-9. doi: 10.1253/circj.cj-14-0204. doi: 10.1253/circj.cj-14-0204
[35]	Chen H, Li JX, Wang H, et al. Correlation between SYNTAX score of coronary heart disease and ultrasound-guided cerebral infarction typing in patients with coronary artery diseases. Chin Circ J 2021; 36(2):144-8.
[36]	Obeid S, Attinger-Toller A, Taramasso M, et al. SYNTAX score Ⅱ in patients with coronary artery disease undergoing percutaneous mitral repair with the MitraClip. Int J Cardiol 2017; 236:375-80. doi: 10.1016/j.ijcard.2017.02.049. doi: 10.1016/j.ijcard.2017.02.049
[37]	Bangalore S, Toklu B, Wetterslev J. Complete versus culprit-only revascularization for ST-segment-elevation myocardial infarction and multivessel disease: a meta-analysis and trial sequential analysis of randomized trials. Circ Cardiovasc Interv 2015; 8(4): 10. doi: 10.1161/circinterventions.114.002142. doi: 10.1161/circinterventions.114.002142
[38]	Lee JM, Rhee TM, Hahn JY, et al. Multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction with cardiogenic shock. J Am Coll Cardiol 2018; 71(8):844-56. doi: 10.1016/j.jacc.2017.12.028. doi: S0735-1097(17)42016-X pmid: 29471935
[39]	٣٩. Wang Y, Zhao X, Zhou P, et al. Culprit-plaque morphology and residual SYNTAX score predict cardiovascular risk in acute myocardial infarction: an optical coherence tomography study. J Atheroscler Thromb 2021; 29(9):1328-41. doi: 10.5551/jat.63103. doi: 10.5551/jat.63103 pmid: 34544957
[40]	Alidoosti M, Saroukhani S, Lotfi-Tokaldany M, et al. Objectifying the level of incomplete revascularization by the residual SYNTAX score and evaluating its impact on the one-year outcome of percutaneous coronary intervention in patients with multi-vessel disease. Cardiovasc Revasc Med 2016; 17(5):308-12. doi: 10.1016/j.carrev.2016.03.009. doi: 10.1016/j.carrev.2016.03.009
[41]	Généreux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol 2012; 59 (24):2165-74. doi: 10.1016/j.jacc.2012.03.010. doi: 10.1016/j.jacc.2012.03.010 pmid: 22483327
[42]	Kochar A, Varshney AS, Wang DE. Residual SYNTAX score after revascularization in cardiogenic shock: when is complete complete? J Am Coll Cardiol 2021; 77(2):156-8. doi: 10.1016/j.jacc.2020.11.034. doi: 10.1016/j.jacc.2020.11.034 pmid: 33446308
[43]	Takahashi K, Serruys PW, Gao C, et al. Ten-year all-cause death according to completeness of revascularization in patients with three-vessel disease or left main coronary artery disease: insights from the SYNTAX extended survival study. Circulation 2021; 144(2):96-109. doi: 10.1161/circulationaha.120.046289. doi: 10.1161/CIRCULATIONAHA.120.046289 pmid: 34011163
[44]	Lee SH, Choi KH, Lee JM, et al. Residual functional SYNTAX score by quantitative flow ratio and improvement of exercise capacity after revascularization. Catheter Cardiovasc Interv 2021; 97(4): E

优先出版

当期目次

过刊浏览

虚拟专题

作者中心

评阅者中心